Objectives: To investigate the prevalence and patterns of major and accessory resistance mutations associated with integrase strand transfer inhibitors (INSTIs), across diverse HIV-1 subtypes in sub-Saharan Africa.
Introduction
Since their first approval for clinical use in 2007, integrase strand transfer inhibitors (INSTIs) for the treatment of HIV-1, have demonstrated remarkable superiority over other drug classes in terms of safety and tolerability, fast viral clearance and high potency. 1 Three drugs have been currently approved: raltegravir, elvitegravir and dolutegravir with cabotegravir and bictegravir being in the final stages of clinical evaluation. Previously reserved as salvage therapy, they have since become the preferred first-line regimen as currently recommended by ART guidelines in high-income countries. 2, 3 Access to INSTIs in resource-limited settings has been restricted because of high prices, but recent collective bargains and agreements for development of generic dolutegravir, have seen their adoption into WHO guidelines as alternative first-line regimens. 4 To date, Botswana and Kenya are the only two countries in sub-Saharan Africa that are rolling out dolutegravir as part of standard first-line ART. However, wide-scale access across the region is anticipated as generic drugs become available and as countries adopt the recent WHO guidelines recommending dolutegravir as the preferred first-line regimen in regions where the prevalence of pre-treatment NNRTI resistance is 10%. 5 Despite their high efficacy, resistance to INSTIs is known to occur, leading to treatment failure. 6, 7 To date .40 mutations have been associated with INSTI resistance, although many of them are thought to be polymorphisms. [8] [9] [10] The primary mutation pathways identified involve mainly substitutions at T66, E92 (elvitegravir), Y143 (elvitegravir plus raltegravir), Q148, N155 and R263 (elvitegravir, raltegravir and dolutegravir) amino acids. 8 In addition to these, some polymorphic mutations play a significant role in rescuing viral fitness and/or increasing the level of resistance. 8 Biochemical studies have shown a subtype-dependent influence of natural polymorphisms on the occurrence and activity of INSTI resistance. [11] [12] [13] [14] For instance, subtype B viruses have been shown to have a higher fitness cost associated with G118R, a recently proposed resistance pathway, compared with subtypes C and CRF_02 AG. 13 Consequently, G118R has rarely been observed in subtype B viruses. It has been postulated that G118R could be an alternative pathway for dolutegravir resistance in non-subtype B viruses, whereas R263K is the preferred pathway for subtype B viruses. 13 The occurrence of G118R is further impacted by a rare natural polymorphism at codon 118 (GGG or GGA) that has a low genetic barrier, facilitating the transition of glycine to arginine (AGG or AGA) through a single point mutation. 15 The prevalence of the G118R mutation may also differ by subtype. Moreover, the impact of other polymorphic mutations in augmenting resistance and rescuing the viral fitness of the G118R mutants was also shown to be subtype dependent. 13 Taken together, these findings indicate that minor differences in polymorphisms between subtypes may influence the emergence of resistance variants, enhance resistance or even lead to the development of new resistance pathways. Nonetheless, patient-derived pre-treatment data on INSTI resistance in sub-Saharan Africa remain scarce.
This study aimed to generate baseline data on INSTI resistance and polymorphisms across the various HIV-1 subtypes in subSaharan Africa, which is necessary for the rollout of INSTI-based regimens. To this end, we assessed the prevalence of naturally occurring major and accessory resistance mutations, including those occurring at low frequencies, in a large international cohort of ART-naive patients from five sub-Saharan African countries representing the major HIV-1 subtypes. Additionally, we also assessed the prevalence and subtype variation of the rare polymorphisms at the G118 position that may facilitate the occurrence of the G118R resistance pathway.
Patients and methods

Study design and population
The Pan-African Studies to Evaluate Resistance Monitoring (PASER-M) study was a prospective cohort of HIV-1-positive adults who initiated ART between 2007 and 2009, at 13 clinical sites in six sub-Saharan African countries, as described previously. 16 We performed a case-control study (1:2 ratio) nested in the cohort to determine the clinical relevance of minority pre-treatment drug-resistant variants. Cases were defined as patients who experienced virological failure after 12 months of first-line NNRTI-based ART (plasma viral load of 400 copies/mL). Controls were defined as patients who had viral suppression (plasma viral load of ,400 copies/mL) at month 12, matched by country, pre-treatment CD4 counts, viral load and age.
The current study presents the analysis of 489 baseline samples collected from participants in the case-control study from five countries, i.e. Kenya, Nigeria, South Africa, Uganda and Zambia.
Ethics
The study was approved by the national and local research ethics committees at the collaborating sites. Participants provided written informed consent at enrolment.
Virological analysis
Archived plasma samples were shipped to the IrsiCaixa laboratory (Badalona, Spain) for ultrasensitive genotyping using next-generation sequencing. Amplification was performed using the pan-HIV-1 pol assay described in the Supplementary Methods (available as Supplementary data at JAC Online). Briefly, viral RNA was extracted from plasma samples using the QiaAmp viral RNA mini kit following the manufacturer's instructions (Qiagen Inc., Chatsworth, CA, USA). Thereafter, a 3448 bp segment of the 5 0 region of the pol gene was generated by a first RT-PCR one-step reaction using the SuperScript TM III One-Step RT_PCR System with Platinum TM TaqDNA Polymerase (ThermoFisher Scientific Inc., Waltham, MA, USA), followed by a nested PCR using Platinum TM Taq DNA Polymerase High Fidelity (ThermoFisher Scientific Inc.). DNA libraries were then purified using the Agencourt AMPure XP PCR Purification system (Beckman Coulter Inc., Brea, CA, USA), quantified using the Quant-iT TM PicoGreen TM dsDNA Assay Kit (ThermoFisher Scientific Inc.) and diluted. Diluted samples were then prepared for sequencing using the Nextera XT DNA Sample Preparation Kit and Nextera XT Index Kit (Illumina, San Diego, CA, USA), according to the manufacturers' instructions. Finally, they were multiplexed into pools of 96 libraries and sequenced using the 500 cycle MiSeq Reagent Kits v0.2 (Illumina).
Assembly of the MiSeq sequence reads (FASTQ) and quality assessment were done using PASeq (https://paseq.org), an automated HIV drug resistance analysis pipeline (IrsiCaixa, Barcelona, Spain). We then generated a list of amino acid substitutions relative to the reference sequence (HXB2). INSTI resistance mutations were defined as (i) major resistance mutations according to the IAS 2017 mutation list, 17 and (ii) accessory mutations as identified by the IAS 2017 mutation list and with a Stanford HIVdb 10 resistance penalty score. 18 Major resistance mutations are those that cause significant reduction in INSTI susceptibility even when they occur alone. Accessory mutations are those that cause only low-level reduction of INSTI susceptibility when they occur alone, but may serve to augment resistance and/or restore the fitness of viral mutants with major resistance mutations.
Resistance was reported at sensitivity thresholds of (i) 20% standard Sanger sequencing threshold, and (ii) cumulative resistance, which includes mutations at sensitivity thresholds of 1%, 2%, 5% and 10%, as there is limited understanding of the role of minority INSTI resistance variants.
Additionally, we assessed subtype variability for the rare polymorphisms (GGG and GGA), which influences the occurrence of the G118R mutation resistance pathway. HIV subtyping was done by the REGA v3.0 subtyping tool. 19 All sequences from this study have been deposited in GenBank (accession numbers MG693785-MG694209). Differences in drug resistance mutation distributions by subtype were assessed by v 2 statistic and Fisher's exact test.
Results
Patient characteristics
Of 489 samples, 425 (87%) were successfully sequenced and analysed; 28 (6%) failed amplification and 36 (7%) either failed sequencing or had a poor quality sequence. Inzaule et al.
Prevalence of major INSTI resistance
We did not observe any major INSTI mutation at the resistance detection threshold of 20%. The cumulative prevalence of major INSTI mutations including those circulating at low-level frequency was 0.2% (1), 0.5% (2), 0.7% (3) and 2.4% (10) at sensitivity thresholds of 10%, 5%, 2% and 1% respectively (Figure 1) . The pattern of major resistance mutations at ,20% threshold was: T66A/I (3, 0.7%), E92G (2, 0.5%), Y143C/S (3, 0.7%), S147G (1, 0.2%) and Q148R (2, 0.5%).
Patterns of accessory INSTI mutations
The prevalence of accessory INSTI mutations was 15.1% (64) at the resistance detection threshold of 20%. The cumulative prevalence of accessory mutations including those at low-level frequency was 15.8% (67), 17.4% (74), 20.0% (85) and 23.3% (99) at sensitivity thresholds of 10%, 5%, 2% and 1% respectively ( Figure 1 ). L74I/M and T97A were the most common accessory INSTI mutations and occurred at a prevalence of 10.4% (44) and 4.0% (17) respectively at the 20% detection threshold and 13.4% (57) and 6.8% (29) at the 1% threshold, respectively (Table 1 ). Other mutations occurring at 20% detection threshold were Q95K (2, 0.5%), E157Q (3, 0.7%) and G163R/K (3, 0.7%).
Sequences from 3.5% (15) of participants harboured .1 drug resistance mutation, which were mainly of L74I/M and T97A accessory mutations (Table S1 ).
Patterns of INSTI resistance by subtype
We observed a variation in the patterns of both major and accessory mutations by subtype (Table 1) . Cumulative prevalence at the 1% threshold for any major mutations was 8.3% (1) in subtype G, 2.4% (5) in C, 2.5% (3) in A, 2.4% (1) for recombinants and none in D. The differences, however, were not of statistical significance (P " 0.450). The major INSTI mutations, E92G and Y143C/S were only observed in subtype A; Q148R in subtype C; and S147G in subtype G. The cumulative prevalence of accessory mutations at 20% detection threshold was highest in subtype G (25%, 3), followed by recombinants (23.8%, 10), A (23.1%, 28), D (11.6%, 5) and subtype C (8.7%, 18). Compared with subtype C, accessory mutations detected at 20% threshold, occurred at statistically significantly higher proportions in subtype A (P , 0.001) and in recombinants (P " 0.009). The cumulative prevalence of accessory mutations including those at low-level frequency (1%) was highest in subtype A (35.5%, 43), followed by recombinants (33.3%, 14 
Natural polymorphisms at codon G118
The overall frequency of polymorphisms at G118 was 6.1% (26) , being 4% (17) for GGA and 2.1% (9) for GGG ( Table 2 ). The frequency of the GGA motif was highest among subtype A genotypes (6.6%, 8) while the GGG was highest among the recombinant viruses (9.5%, 4). Subtype D had the lowest frequency for the rare polymorphisms, having only one participant with the GGA motif (2.3%), while none were present in subtype G.
Discussion
This observational study among patients enrolled in a large multicountry African cohort showed low prevalence of major INSTI resistance mutations, which were present only at a low-level detection threshold of ,20%. To the best of our knowledge, this is one of the first large-scale studies in Africa to assess background resistance to Primary HIV integrase resistance in Africa JAC INSTI drugs. Although the samples analysed date back to 2007-09, the findings are still highly relevant today, given that the use of INSTIs in the region has been virtually non-existent over the past decade. Our findings provide important evidence to guide the widescale implementation of dolutegravir-based regimens in the region. Recent data from WHO surveys assessing pre-treatment drug resistance found that in three of four countries surveyed, .10% of people who were newly initiating ART had HIV strains resistant to NNRTIs. Subsequently, the WHO issued new guidelines recommending a rapid transition to dolutegravir-based first-line treatment in countries with a pre-treatment drug resistance prevalence of 10% and in persons with previous antiretroviral exposure. 5, 20 Moreover, more countries are expected to transition to dolutegravir-based treatment, regardless of the prevalence of pretreatment NNRTI resistance, owing to availability of a low-cost generic fixed-dose combination (tenofovir/lamivudine/dolutegravir, US$75 per person per year). 20 Similar findings for the occurrence of low-frequency major resistance mutations in INSTI-naive patients have previously been reported, but the clinical relevance remains uncertain. 21, 22 A secondary analysis of patients participating in the BENCHMRK-1 raltegravir clinical trial in North and South America, found a higher but non-significant prevalence of baseline INSTI major mutations (Y143R/C/H, Q148R/H/K and N155H) in patients with virological failure compared with those with sustained virological suppression, which was present only at frequencies of ,1%. 21 Another study on INSTI-naive patients initiating raltegravir-based ART also found a high prevalence of Q148R variants, which were present mainly at frequency levels of ,1%, 22 with no significant impact on virological response. 22 However, both studies were limited by a small sample size and restricted to HIV-1 subtype B.
Accessory resistance mutations occurred mainly at a higher resistance detection threshold (20%) and included L74I/M, Q95K, T97A, E157Q and G163R/K. L74I/M and T97A were the most common accessory mutations and similar to previous reports, were more frequent in participants infected with subtype A, G and recombinant viruses. 23, 24 L74I/M are polymorphic mutations Recombinants AD (n " 14), CRF_02AG (n " 9), AC (n " 6), AG (n " 4), AG complex recombinants (n " 6), DG (n " 1), CD (n " 2). Recombinants AD (14) , CRF_02AG (9), AC (6), AG (4), AG complex recombinants (6), DG (1), CD (2).
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commonly selected by all the three INSTI drugs and occur at levels of between 0.5% and 20% in untreated populations with high prevalence in subtype A, G and A/G recombinants. 23 However, it does not affect INSTI susceptibility unless in combination with other major INSTI resistance mutations, mainly the Q148H/K/R mutation.
18 T97A on the other hand is mainly selected among patients on raltegravir and elvitegravir and occurs in 1%-5% of untreated patients. 23 Similarly, T97A has minimal effect on INSTI susceptibility on its own but leads to significant reduction in raltegravir and elvitegravir susceptibility in combination with Y143 and N155H major resistance mutations.
18 Q95K is a non-polymorphic accessory mutation selected in patients on raltegravir and elvitegravir. 23 On its own it does not affect INSTI susceptibility but enhances resistance of N155H mutants to raltegravir and elvitegravir. 18, 25 E157Q is a polymorphic accessory mutation selected in vitro by elvitegravir and in raltegravir-treated patients. 23 On its own, E157Q has no significant effect on INSTI susceptibility but reduces susceptibility of raltegravir and elvitegravir in the presence of an N155H major resistance mutation. 18 A recent in vitro study showed that it could also play a compensatory role in restoring integrase activity of R263K mutants as well as augmenting their resistance to dolutegravir.
26 G163R/K on the other hand is a nonpolymorphic accessory mutation occurring naturally mainly in subtype F viruses but is commonly selected in raltegravir-treated patients. 23 On its own it has minimal effect on INSTI susceptibility but increases resistance to raltegravir and elvitegravir when occurring jointly with Y143 and N155H mutations. 18 There is a need to monitor continuously for new resistance patterns that may have not been previously observed among subtype B viruses. Recent studies have suggested an alternative resistance pathway for dolutegravir that involves the G118R mutation selected mainly in non-subtype B viruses. 13 An in-depth analysis revealed that this could be facilitated by rare polymorphisms at the G118 position, which require a single-point transition mutation from glycine (GGA or GGG) to arginine (AGA or AGG). 15 This is in contrast to the dominant polymorphisms GGC and GGT that require either a two-point mutation (GGC!AGA or GGT!AGA) or a single-step unfavourable transversion (GGC!CGC and GGT!CGT, respectively). Moreover, the rare polymorphism at the G118 position is also an APOBEC3G/F hotspot, and may thus be amenable to APOBEC3G/ F-mediated G to A transitions leading to resistance. 27 A previous analysis from the Los Alamos database showed that the rare G118 polymorphisms occur at a low prevalence of 2.5% ranging from 0% for subtypes F and G to 1.4% for subtype B, to 3.8% in CRF01_AE recombinants. 15 In our study, however, the overall frequency was 6.1% with frequencies as high as 8.3% and 11.9% in subtype A and recombinants respectively. These findings may suggest a higher propensity for occurrence of this mutation in non-subtype B viruses. When the G118R occurs together with the T66I/A and E138K mutations, this results in a 6.5-fold resistance to dolutegravir. 15 These findings indicate the need for close monitoring of dolutegravir implementation in the region, as there is still inadequate information on INSTI resistance mutations that may lead to treatment failure in patients infected with non-subtype B viruses.
There are some study limitations. The nested case-control design may not provide a true random sample of the total cohort and may have led to under-representation of the major HIV-1 subtypes. This limits our ability to generalize our results, which is however partially compensated by the large sample size.
Altogether these findings provide some reassurance of the potential effectiveness of INSTI-based regimens in these settings, as more countries adapt and implement the recent guidelines advocating for dolutegravir-based first-line treatment. However, real-life data on treatment response and resistance mutations selected by dolutegravir in non-B subtypes are still required. This is particularly important, owing to the possibility of new subtypedependent resistance pathways such as G118R, which may considerably impact the efficacy of dolutegravir. Further studies are needed to understand the potential impact of the low-frequency INSTI resistance mutations observed in this and other studies. In addition, continuous surveillance for both transmitted and acquired resistance is necessary following reports from Western countries showing the emergence of INSTI resistance in both naive and treated patients. 6, 7, 28, 29 In conclusion, we observed low prevalence of major INSTI resistance mutations, which occurred only at a low-level detection threshold. These findings offer some reassurance of the effectiveness of INSTI-based regimens in sub-Saharan Africa across the different major circulating HIV-1 subtypes.
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